Meropenem Approved to Treat Very Young Infants
May 19, 2015 - The U.S. Food and Drug Administration approved meropenem, an intravenous (IV) broad-spectrum antibiotic for a new indication. Meropenem is now indicated to treat complicated intra-abdominal infections for children younger than three months of age. Previously, it was approved to treat complicated intra-abdominal infections and complicated skin infections for adults and children at least three months old and is also indicated to treat children three months old and older who have bacterial meningitis. As member of the carbapenem therapy class, meropenem can withstand an enzyme (β-lactamase) that is released by many bacteria to resist some other antibiotics. It is available as generics and as the brand Merrem® I.V. which is manufactured by AstraZeneca.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability. All trademarks are the property of their respective owners.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.